Novolog

The page discusses the future of hospital stays, suggesting home hospitalization may replace traditional hospital beds.

The page highlights the need for new treatments for chronic diabetes beyond blood sugar management, citing Israel’s large diabetic population.

Novolog is an Israeli company aiming to improve healthcare in Israel and adapt it to future challenges.

Novolog reports ₪451.9 million in Q2 2026 revenue alongside a net income of just ₪0.6 million, reflecting a severe profit squeeze despite revenue growth. The company’s trailing twelve-month loss raises concerns over its ability to sustain a dividend, which is not currently covered by earnings. Stock performance shows volatility, with a recent decline over the past week despite a monthly gain.

Aug 2026Simply Wall StNews article

Novolog (Pharm-Up 1966) Ltd reports second-quarter 2026 sales of **ILS 451.87 million**, up from **ILS 441.69 million** in the same period last year. The company’s net income drops sharply to **ILS 0.559 million**, down from **ILS 4.78 million** year-over-year. Basic and diluted earnings per share also decline significantly, falling to **ILS 0.001** from **ILS 0.0094** in 2025. The results cover the quarter and first six months ending June 30, 2026.

Aug 2026MarketScreenerNews article

Novolog (Pharm-Up 1966) Ltd reports **ILS 1.8 billion in sales** and **ILS 4.12 million in net income** for 2025, marking a decline from **ILS 2.02 billion in sales** and **ILS 39.54 million in net income** in the prior year. The company’s financial performance shows reduced revenue and profitability compared to 2024. The earnings update covers the full year ending December 31, 2025.

Mar 2026MarketScreenerNews article

Novolog reports a **23% revenue increase** in its 2024 presentation slides. The company also announces its **return to profitability** after prior losses. Financial details and operational updates are outlined in the disclosed materials.

Aug 2025Investing.comNews article